Pay in 4 interest-free payments of $5.69 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
For pharma manufacturers, the sudden popularity of GLP-1 drugs has placed increased strain on the medical supply chain and subsequent pressure to avoid bottle necks
From a drug-development perspective, METRNL illustrates the limitations of receptor-centric paradigms
This lack of benefit stands in contrast with the significant or nearly-significant reduction in macrovascular risk reported with liraglutide, semaglutide and exenatide [51,52,53], which also enhance signaling through the GLP-1 receptor [54]
extend our understanding of the mechanism of action of metformin and provide further insights into the benefits of combining metformin with incretin-based drugs to combat diabetes
et al: Drug repurposing of FDA compounds against -Glucosidase for the treatment of type 2 diabetes: insights from molecular docking and molecular dynamics simulations
